Arrowstreet Capital Limited Partnership Buys 658,655 Shares of Relx Plc (NYSE:RELX)

Arrowstreet Capital Limited Partnership raised its holdings in Relx Plc (NYSE:RELX - Free Report) by 50.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,968,739 shares of the technology company's stock after buying an additional 658,655 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.11% of Relx worth $89,420,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Natixis Advisors LLC boosted its holdings in Relx by 2.8% in the 4th quarter. Natixis Advisors LLC now owns 1,202,592 shares of the technology company's stock worth $54,622,000 after buying an additional 32,739 shares during the period. Raymond James Financial Inc. purchased a new position in Relx during the fourth quarter valued at approximately $44,516,000. JPMorgan Chase & Co. increased its holdings in Relx by 14.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company's stock worth $39,225,000 after acquiring an additional 104,999 shares during the period. Reynders McVeigh Capital Management LLC boosted its holdings in Relx by 31.8% in the 3rd quarter. Reynders McVeigh Capital Management LLC now owns 495,004 shares of the technology company's stock valued at $23,493,000 after purchasing an additional 119,405 shares during the period. Finally, American Century Companies Inc. grew its position in shares of Relx by 5.1% during the 4th quarter. American Century Companies Inc. now owns 405,100 shares of the technology company's stock valued at $18,400,000 after purchasing an additional 19,728 shares in the last quarter. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of brokerages have recently issued reports on RELX. Barclays upgraded Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. Redburn Atlantic began coverage on shares of Relx in a research note on Wednesday, January 8th. They issued a "buy" rating for the company. The Goldman Sachs Group initiated coverage on shares of Relx in a research report on Wednesday, March 26th. They set a "buy" rating on the stock. Finally, StockNews.com lowered shares of Relx from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Relx presently has a consensus rating of "Buy".

Relx Trading Down 6.3 %

Relx stock traded down $3.23 during mid-day trading on Friday, hitting $48.21. The company's stock had a trading volume of 1,321,661 shares, compared to its average volume of 722,723. The business has a 50 day moving average price of $49.62 and a 200-day moving average price of $47.91. Relx Plc has a 12 month low of $40.25 and a 12 month high of $51.99. The stock has a market cap of $89.48 billion, a price-to-earnings ratio of 25.92, a price-to-earnings-growth ratio of 2.73 and a beta of 0.84. The company has a debt-to-equity ratio of 1.46, a current ratio of 0.52 and a quick ratio of 0.47.

Relx Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Friday, May 9th will be paid a $0.5586 dividend. This is a boost from Relx's previous semi-annual dividend of $0.23. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, May 9th. Relx's payout ratio is 59.68%.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.